Halozyme shares slip 4.28% despite 39% revenue growth and slightly higher guidance
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Halozyme Therapeutics (NASDAQ:HALO) shares fell 4.28% to $117.69 at 9:35 a.m. ET on Friday, November 6, after the drug-delivery company reported third-quarter revenue of $493 million, up 39%, and nudged up its 2026 targets. The quarter…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe stock reacts negatively because the 2026 guidance raise is seen as too small.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Halozyme reported third-quarter revenue of $493 million, up 39%.
- 02Royalty revenue rose 44% to $341 million.
- 03For 2026 the company expects revenue between $1.860 and $1.925 billion.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets